Chlorotyrosine exerts renal effects and antagonizes renal and gastric responses to atrial natriuretic peptide

Q. M. Chen, D. D. Smyth, J. K. McKenzie, G. B. Glavin, J. G. Gu, Jonathan Geiger, F. S. LaBella

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

3-Chloro-L-tyrosine (3CT) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme for catecholamine synthesis. In vivo inhibition of tyrosine hydroxylase results in lower catecholamine levels. 3CT (0.5 mg/kg), administered as a bolus i.v. to anesthetized uninephrectomized rats, elicited increases of 72% and 44% in urinary sodium concentration and volume, respectively, whereas a dose of 1 mg/kg caused increases of 27% and 29%. 3CT, 1 mg/kg, resulted in a 2-fold increase in plasma aldosterone (ALD); 0.5 mg/kg was without significant effect. At a dose of 1 mg/kg 3CT significantly antagonized the renal effects of atrial natriuretic peptide (ANP) (1.5 μg kg-1 min-1 by intrarenal infusion), expressed as an enhanced excretion of urine volume (102 ± 14 vs. 70 ± 11 μl/min) and sodium (16.1 ± 1.8 vs. 11.5 ± 1.7 μEq/min) and increased osmolar clearance (171 ± 12 vs. 144 ± 13 μl/min). A dose of 0.5 mg/kg of 3CT did not produce these same responses to ANP. The increased urine flow caused by 3CT may reflect reduced norepinephrine synthesis. The inverse dose-effect relationship of 3CT on urine flow rate may result from concomitant depletion of dopamine (DA) and elevated circulating ALD. The antagonism of 3CT on responses to ANP is not at the receptor level, because 3CT did not compete for [125I] ANP binding or inhibit ANP-stimulated guanylate cyclase in kidney cell membranes. It was proposed that the reduced basal sympathetic and renal DA tone, together with the elevated ALD level, account for this antagonism. Furthermore, 3CT antagonized ANP in another system: 3CT given i.p. at doses of 0.1, 0.2 and 0.5 mg/kg antagonized gastric acid secretion in response to ANP given i.c.v.

Original languageEnglish (US)
Pages (from-to)709-716
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume269
Issue number2
StatePublished - Jan 1 1994

Fingerprint

Atrial Natriuretic Factor
Stomach
Kidney
Aldosterone
Tyrosine 3-Monooxygenase
Urine
Catecholamines
Dopamine
3-chlorotyrosine
Sodium
Guanylate Cyclase
Gastric Acid
Norepinephrine
Cell Membrane

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Chen, Q. M., Smyth, D. D., McKenzie, J. K., Glavin, G. B., Gu, J. G., Geiger, J., & LaBella, F. S. (1994). Chlorotyrosine exerts renal effects and antagonizes renal and gastric responses to atrial natriuretic peptide. Journal of Pharmacology and Experimental Therapeutics, 269(2), 709-716.

Chlorotyrosine exerts renal effects and antagonizes renal and gastric responses to atrial natriuretic peptide. / Chen, Q. M.; Smyth, D. D.; McKenzie, J. K.; Glavin, G. B.; Gu, J. G.; Geiger, Jonathan; LaBella, F. S.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 269, No. 2, 01.01.1994, p. 709-716.

Research output: Contribution to journalArticle

Chen, Q. M. ; Smyth, D. D. ; McKenzie, J. K. ; Glavin, G. B. ; Gu, J. G. ; Geiger, Jonathan ; LaBella, F. S. / Chlorotyrosine exerts renal effects and antagonizes renal and gastric responses to atrial natriuretic peptide. In: Journal of Pharmacology and Experimental Therapeutics. 1994 ; Vol. 269, No. 2. pp. 709-716.
@article{a6339273c2654c5ba351ae41b6ad5540,
title = "Chlorotyrosine exerts renal effects and antagonizes renal and gastric responses to atrial natriuretic peptide",
abstract = "3-Chloro-L-tyrosine (3CT) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme for catecholamine synthesis. In vivo inhibition of tyrosine hydroxylase results in lower catecholamine levels. 3CT (0.5 mg/kg), administered as a bolus i.v. to anesthetized uninephrectomized rats, elicited increases of 72{\%} and 44{\%} in urinary sodium concentration and volume, respectively, whereas a dose of 1 mg/kg caused increases of 27{\%} and 29{\%}. 3CT, 1 mg/kg, resulted in a 2-fold increase in plasma aldosterone (ALD); 0.5 mg/kg was without significant effect. At a dose of 1 mg/kg 3CT significantly antagonized the renal effects of atrial natriuretic peptide (ANP) (1.5 μg kg-1 min-1 by intrarenal infusion), expressed as an enhanced excretion of urine volume (102 ± 14 vs. 70 ± 11 μl/min) and sodium (16.1 ± 1.8 vs. 11.5 ± 1.7 μEq/min) and increased osmolar clearance (171 ± 12 vs. 144 ± 13 μl/min). A dose of 0.5 mg/kg of 3CT did not produce these same responses to ANP. The increased urine flow caused by 3CT may reflect reduced norepinephrine synthesis. The inverse dose-effect relationship of 3CT on urine flow rate may result from concomitant depletion of dopamine (DA) and elevated circulating ALD. The antagonism of 3CT on responses to ANP is not at the receptor level, because 3CT did not compete for [125I] ANP binding or inhibit ANP-stimulated guanylate cyclase in kidney cell membranes. It was proposed that the reduced basal sympathetic and renal DA tone, together with the elevated ALD level, account for this antagonism. Furthermore, 3CT antagonized ANP in another system: 3CT given i.p. at doses of 0.1, 0.2 and 0.5 mg/kg antagonized gastric acid secretion in response to ANP given i.c.v.",
author = "Chen, {Q. M.} and Smyth, {D. D.} and McKenzie, {J. K.} and Glavin, {G. B.} and Gu, {J. G.} and Jonathan Geiger and LaBella, {F. S.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "269",
pages = "709--716",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Chlorotyrosine exerts renal effects and antagonizes renal and gastric responses to atrial natriuretic peptide

AU - Chen, Q. M.

AU - Smyth, D. D.

AU - McKenzie, J. K.

AU - Glavin, G. B.

AU - Gu, J. G.

AU - Geiger, Jonathan

AU - LaBella, F. S.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - 3-Chloro-L-tyrosine (3CT) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme for catecholamine synthesis. In vivo inhibition of tyrosine hydroxylase results in lower catecholamine levels. 3CT (0.5 mg/kg), administered as a bolus i.v. to anesthetized uninephrectomized rats, elicited increases of 72% and 44% in urinary sodium concentration and volume, respectively, whereas a dose of 1 mg/kg caused increases of 27% and 29%. 3CT, 1 mg/kg, resulted in a 2-fold increase in plasma aldosterone (ALD); 0.5 mg/kg was without significant effect. At a dose of 1 mg/kg 3CT significantly antagonized the renal effects of atrial natriuretic peptide (ANP) (1.5 μg kg-1 min-1 by intrarenal infusion), expressed as an enhanced excretion of urine volume (102 ± 14 vs. 70 ± 11 μl/min) and sodium (16.1 ± 1.8 vs. 11.5 ± 1.7 μEq/min) and increased osmolar clearance (171 ± 12 vs. 144 ± 13 μl/min). A dose of 0.5 mg/kg of 3CT did not produce these same responses to ANP. The increased urine flow caused by 3CT may reflect reduced norepinephrine synthesis. The inverse dose-effect relationship of 3CT on urine flow rate may result from concomitant depletion of dopamine (DA) and elevated circulating ALD. The antagonism of 3CT on responses to ANP is not at the receptor level, because 3CT did not compete for [125I] ANP binding or inhibit ANP-stimulated guanylate cyclase in kidney cell membranes. It was proposed that the reduced basal sympathetic and renal DA tone, together with the elevated ALD level, account for this antagonism. Furthermore, 3CT antagonized ANP in another system: 3CT given i.p. at doses of 0.1, 0.2 and 0.5 mg/kg antagonized gastric acid secretion in response to ANP given i.c.v.

AB - 3-Chloro-L-tyrosine (3CT) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme for catecholamine synthesis. In vivo inhibition of tyrosine hydroxylase results in lower catecholamine levels. 3CT (0.5 mg/kg), administered as a bolus i.v. to anesthetized uninephrectomized rats, elicited increases of 72% and 44% in urinary sodium concentration and volume, respectively, whereas a dose of 1 mg/kg caused increases of 27% and 29%. 3CT, 1 mg/kg, resulted in a 2-fold increase in plasma aldosterone (ALD); 0.5 mg/kg was without significant effect. At a dose of 1 mg/kg 3CT significantly antagonized the renal effects of atrial natriuretic peptide (ANP) (1.5 μg kg-1 min-1 by intrarenal infusion), expressed as an enhanced excretion of urine volume (102 ± 14 vs. 70 ± 11 μl/min) and sodium (16.1 ± 1.8 vs. 11.5 ± 1.7 μEq/min) and increased osmolar clearance (171 ± 12 vs. 144 ± 13 μl/min). A dose of 0.5 mg/kg of 3CT did not produce these same responses to ANP. The increased urine flow caused by 3CT may reflect reduced norepinephrine synthesis. The inverse dose-effect relationship of 3CT on urine flow rate may result from concomitant depletion of dopamine (DA) and elevated circulating ALD. The antagonism of 3CT on responses to ANP is not at the receptor level, because 3CT did not compete for [125I] ANP binding or inhibit ANP-stimulated guanylate cyclase in kidney cell membranes. It was proposed that the reduced basal sympathetic and renal DA tone, together with the elevated ALD level, account for this antagonism. Furthermore, 3CT antagonized ANP in another system: 3CT given i.p. at doses of 0.1, 0.2 and 0.5 mg/kg antagonized gastric acid secretion in response to ANP given i.c.v.

UR - http://www.scopus.com/inward/record.url?scp=0028338886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028338886&partnerID=8YFLogxK

M3 - Article

VL - 269

SP - 709

EP - 716

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -